CAI financial statements
The full income statement, balance sheet, and cash-flow statement for Caris Life Sciences Inc. (CAI), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| Revenue | 812M+97.0% | 412M+34.7% | 306M | |
| Research & development | 102M-10.8% | 114M-2.5% | 117M | |
| Selling, general & administrative | 225M+32.8% | 169M+13.6% | 149M | |
| General & administrative | 225M+32.8% | 169M+13.6% | 149M | |
| Selling & marketing | 168M+9.8% | 153M+6.8% | 143M | |
| Operating income | 45.1M+117.5% | -257M+19.5% | -320M | |
| Interest expense | 56.9M+13.6% | 50.0M+58.3% | 31.6M | |
| Other non-operating income | -20.6M-5791.1% | -349K+97.2% | -12.6M | |
| Pre-tax income | -68.1M+75.8% | -282M+17.4% | -341M | |
| Income tax | 0.00 | 0.00 | 0.00 | |
| -68.1M+75.8% | -282M+17.4% | -341M | ||
| Net income to common | -538M-42.2% | -378M+18.2% | -463M | |
| -$3.22+69.8% | -$10.66+19.5% | -$13.24 | ||
| EPS (basic) | -$3.22+69.8% | -$10.66+19.5% | -$13.24 | |
| Weighted-avg shares (basic) | 167M+371.0% | 35.5M+1.6% | 34.9M | |
| Weighted-avg shares (diluted) | 167M+371.0% | 35.5M+1.6% | 34.9M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| 998M+362.5% | 216M | — | ||
| Cash & equivalents | 796M+1145.2% | 64.0M | — | |
| Short-term investments | 2.29M+4.3% | 2.20M | — | |
| Accounts receivable | 112M+27.1% | 88.2M | — | |
| Prepaid expenses | 21.9M+8.2% | 20.3M | — | |
| Other current assets | 2.35M-64.9% | 6.71M | — | |
| 1.13B+227.5% | 344M | — | ||
| Property, plant & equipment | 63.2M-6.9% | 67.8M | — | |
| Operating lease right-of-use | 39.8M+14.0% | 35.0M | — | |
| Goodwill | 19.3M+0.0% | 19.3M | — | |
| Other non-current assets | 45.3M+11.0% | 40.8M | — | |
| 127M-23.1% | 165M | — | ||
| Accounts payable | 39.2M+41.1% | 27.8M | — | |
| Accrued liabilities | 87.8M+13.2% | 77.5M | — | |
| Deferred revenue | 24.5M+227.9% | 7.47M | — | |
| Short-term & current debt | 169K+181.2% | 60.1K | — | |
| Current lease liability | 6.36M+4.6% | 6.08M | — | |
| Finance lease liability (current) | 169K+87.8% | 90.0K | — | |
| 548M-11.7% | 621M | — | ||
| Long-term debt | 379M+18.6% | 319M | — | |
| Deferred revenue (non-current) | 0.00 | — | — | |
| Non-current lease liability | 42.3M+9.5% | 38.7M | — | |
| Operating lease liability (total) | 48.7M | — | — | |
| Finance lease liability (total) | 542K | — | — | |
| Finance lease liability | 373K+53.5% | 243K | — | |
| Other non-current liabilities | 42.4M-4.6% | 44.4M | — | |
| 577M+123.1% | -2.50B-16.5% | -2.14B | ||
| Preferred stock | 0.00 | 0.00 | — | |
| Common stock | 283K+644.7% | 38.0K | — | |
| Additional paid-in capital | 3.14B | 0.00 | — | |
| Retained earnings | -2.55B-3.1% | -2.47B | — | |
| Treasury stock | 16.9M+5020.0% | 330K | — | |
| Accumulated other comprehensive income | 936K+345.7% | 210K | — | |
| Total liabilities & equity | 1.13B+227.5% | 344M | — | |
| Common shares issued | 284M+674.5% | 36.7M | — | |
| Common shares outstanding | 283M+674.0% | 36.5M | — | |
| Shares outstanding (cover) | 283M | — | — | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| 83.2M+133.9% | -245M+11.2% | -276M | ||
| Depreciation & amortization | 22.6M-53.8% | 48.9M-0.2% | 49.0M | |
| Share-based compensation | 70.0M+275.5% | 18.6M+22.3% | 15.2M | |
| Change in receivables | 29.8M-11.9% | 33.8M+124.2% | 15.1M | |
| Change in payables | 11.0M+4982.7% | -226K-103.2% | 7.17M | |
| -16.3M-130.7% | 52.9M-75.4% | 215M | ||
| Capital expenditure | 16.3M+92.6% | 8.44M-62.2% | 22.3M | |
| Free cash flow | 66.9M+126.4% | -254M+15.0% | -298M | |
| Acquisitions | 0.00 | 0.00 | 0.00 | |
| Sales/maturities of investments | 0.00-100.0% | 61.4M-79.6% | 300M | |
| 665M+232.0% | 200M+1876.8% | 10.1M | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | |
| Common stock repurchased | 113K | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | |
| Net change in cash | 732M+9026.2% | 8.02M+115.7% | -51.1M | |
| Interest paid | 43.5M-11.2% | 49.0M+210.7% | 15.8M | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| Market cap | 7.62B | — | — | |
| P/S | 9.4× | — | — | |
| P/B | 13.2× | — | — | |
| P/FCF | 114.0× | — | — | |
| FCF yield | 0.88% | — | — | |
| Source filing | 10-K | 10-K | 10-K |
About this data
Source: CAI’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all CAI filings on SEC EDGAR → Not investment advice.